AR047621A1 - Derivados de n-tiazol-2- il-benzamida - Google Patents
Derivados de n-tiazol-2- il-benzamidaInfo
- Publication number
- AR047621A1 AR047621A1 ARP040103822A ARP040103822A AR047621A1 AR 047621 A1 AR047621 A1 AR 047621A1 AR P040103822 A ARP040103822 A AR P040103822A AR P040103822 A ARP040103822 A AR P040103822A AR 047621 A1 AR047621 A1 AR 047621A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- aryl
- alkylamino
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se relaciona con compuestos ligandos del receptor A2A, tales como antagonistas, agonistas, agonistas inversos o agonistas parciales, y son utiles en el tratamiento de trastornos neurologicos y psiquiátrico donde se presenta compromiso de un receptor A2A. Reivindicacion 1: Uso de un compuesto de formula (1), en donde R1 y R6 son, de manera independiente, hidrogeno, alquilo C1-6 o halogeno; R2-R5 se seleccionan de manera independiente entre el grupo que consiste en: hidrogeno, halogeno, ciano, OH, NH2, nitro, alquilo C1-6, arilo, aril-alquiloC1-6, heteroaril-alquiloC1-6, cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-6, alcoxi C1-6, aril-alcoxi C1-6, alquilo C1-6-amino y aril-alquilamino C1-6, en donde cada alquilo, alcoxi o arilo puede estar opcionalmente sustituido con uno o más halogeno, ciano, alquilo C1-6, alcoxi C1-6 o alcoxi C1-6-alcoxi C1-6; o R4 y R5 juntos son X-(CH2)n-Y, en donde X e Y se seleccionan de modo independiente entre el grupo que consiste en CH2, NH y O; n es 1, 2 o 3; y R2 y R3 se definen segun lo descripto anteriormente; A es *NR8-CO, *CO-NR9, *NR8-CS o *CS-NR9, en donde R8 y R9 se seleccionan de manera independiente entre el grupo que consiste en hidrogeno y alquilo C1-6, o R8 junto con R3 son alquileno C2-3 o CH2CH2O, en donde el oxígeno está unido al anillo fenilo, y el * indica el átomo que está unido al anillo fenilo; y R7 se selecciona entre el grupo que consiste en alquilo C1-8, arilo, heteroarilo, aril-alquilo C1- 6, heteroari-alquilo C1-6, cicloalquilo C3-8, cicloalquilo C3-8-alquilo C1-6, alcoxi C1-6, aril-alcoxi C1-6, heteroaril-alcoxi C1-6, alquilamino, aril-alquilamino C1-6, heteroaril-alquilamino C1-6, di-(alquilo C1-6)-amino, 2,3-dihidrobenzo- [1,4]dioxin-2-ilo o adamant-1-il-metilo, en donde cada alquilo y cicloalquilo puede estar opcionalmente sustituido con uno o más halogeno, ciano, hidroxi, oxo, alcoxi C1-6 o NR10R11, en donde R10 y R11 en forma independiente son hidrogeno o alquilo C1-6, o R10 y R11 junto con el nitrogeno forman un anillo alifático de 5, 6 o 7 miembros que en forma opcional puede contener otro heteroátomo seleccionado entre N y O, y cada arilo puede estar opcionalmente sustituido con uno o más halogeno, ciano, hidroxi, nitro, alquilo C1-6, alcoxi C1-6, acilo C1-6, NR10R11 en donde R10 y R11 en forma independiente son hidrogeno o alquilo C1-6, o R10 y R11 junto con el nitrogeno forman un anillo alifático de 5, 6 o 7 miembros que en forma opcional puede contener otro heteroátomo seleccionado entre N y O; o un grupo Z-(CH2)m-W, en donde Z y W están unidos a dos átomos de carbono adyacentes y se seleccionan de manera independiente entre el grupo que comprende CH2, NH y O; y m es 1, 2 o 3; siempre que cuando R7 está unido a nitrogeno, entonces R7 no es alcoxi C1-6, aril-alcoxi C1-6, heteroaril-alcoxi C1-6, alquilamino C1-6, aril-alquilamino C1-6, heteroaril-alquilamino C1-6 o di-(alquilo C1-6)-amino; y sus sales de adicion farmacéuticamente aceptables; para la elaboracion de un medicamento para el tratamiento de una enfermedad donde se presenta compromiso de un receptor A2A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301579 | 2003-10-27 | ||
| DKPA200400229 | 2004-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047621A1 true AR047621A1 (es) | 2006-02-01 |
Family
ID=34524309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103822A AR047621A1 (es) | 2003-10-27 | 2004-10-21 | Derivados de n-tiazol-2- il-benzamida |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20060154974A1 (es) |
| EP (2) | EP1803455A1 (es) |
| JP (1) | JP2007509083A (es) |
| KR (1) | KR20060093726A (es) |
| AR (1) | AR047621A1 (es) |
| AT (1) | ATE354365T1 (es) |
| AU (1) | AU2004283019A1 (es) |
| BR (1) | BRPI0415661A (es) |
| CA (1) | CA2542816A1 (es) |
| CO (1) | CO5690582A2 (es) |
| CY (1) | CY1106526T1 (es) |
| DE (1) | DE602004004925T2 (es) |
| DK (1) | DK1682129T3 (es) |
| EA (2) | EA010790B1 (es) |
| ES (1) | ES2279414T3 (es) |
| HR (1) | HRP20070194T3 (es) |
| IL (1) | IL175189A0 (es) |
| IS (1) | IS8364A (es) |
| ME (1) | MEP6708A (es) |
| MX (1) | MXPA06004436A (es) |
| NO (1) | NO20062417L (es) |
| PL (1) | PL1682129T3 (es) |
| PT (1) | PT1682129E (es) |
| RS (1) | RS20060289A (es) |
| SG (1) | SG147472A1 (es) |
| SI (1) | SI1682129T1 (es) |
| TW (1) | TW200524887A (es) |
| WO (1) | WO2005039572A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106040A1 (en) | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| CA2581105A1 (en) | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
| US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
| TW200720264A (en) * | 2005-04-25 | 2007-06-01 | Lundbeck & Co As H | Pro-drugs of n-thiazol-2-yl-benzamide derivatives |
| WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
| LT1921077T (lt) * | 2005-08-02 | 2017-09-25 | Kyowa Hakko Kirin Co., Ltd. | Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| RU2483722C1 (ru) * | 2012-05-22 | 2013-06-10 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| MY186311A (en) | 2013-12-20 | 2021-07-08 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE855120C (de) * | 1950-10-08 | 1953-01-05 | Schering Ag | Verfahren zur Herstellung von Aminosalicylsaeureamiden |
| JP2903339B2 (ja) * | 1990-10-12 | 1999-06-07 | 大日精化工業株式会社 | 電子写真感光体 |
| US6121301A (en) * | 1996-10-24 | 2000-09-19 | Zeria Pharmaceutical Co., Ltd. | Substituted benzoylaminothiazole derivatives and drugs containing the same |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| WO2002059100A1 (fr) * | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Composes halogene ayant un agonisme envers le recepteur de thrombopoietine |
| US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
| TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| SI3002283T1 (en) * | 2003-12-26 | 2018-06-29 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
| US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
-
2004
- 2004-10-08 TW TW093130498A patent/TW200524887A/zh unknown
- 2004-10-21 AR ARP040103822A patent/AR047621A1/es not_active Application Discontinuation
- 2004-10-25 SI SI200430225T patent/SI1682129T1/sl unknown
- 2004-10-25 CA CA002542816A patent/CA2542816A1/en not_active Abandoned
- 2004-10-25 EA EA200600860A patent/EA010790B1/ru not_active IP Right Cessation
- 2004-10-25 PL PL04762951T patent/PL1682129T3/pl unknown
- 2004-10-25 MX MXPA06004436A patent/MXPA06004436A/es active IP Right Grant
- 2004-10-25 AU AU2004283019A patent/AU2004283019A1/en not_active Abandoned
- 2004-10-25 WO PCT/DK2004/000733 patent/WO2005039572A1/en active IP Right Grant
- 2004-10-25 EP EP07102639A patent/EP1803455A1/en not_active Withdrawn
- 2004-10-25 BR BRPI0415661-7A patent/BRPI0415661A/pt not_active IP Right Cessation
- 2004-10-25 JP JP2006535952A patent/JP2007509083A/ja not_active Withdrawn
- 2004-10-25 ES ES04762951T patent/ES2279414T3/es active Active
- 2004-10-25 PT PT04762951T patent/PT1682129E/pt unknown
- 2004-10-25 RS YUP-2006/0289A patent/RS20060289A/sr unknown
- 2004-10-25 SG SG200807988-1A patent/SG147472A1/en unknown
- 2004-10-25 KR KR1020067008181A patent/KR20060093726A/ko not_active Application Discontinuation
- 2004-10-25 EP EP04762951A patent/EP1682129B1/en active Active
- 2004-10-25 EA EA200801734A patent/EA200801734A1/ru unknown
- 2004-10-25 ME MEP-67/08A patent/MEP6708A/xx unknown
- 2004-10-25 AT AT04762951T patent/ATE354365T1/de not_active IP Right Cessation
- 2004-10-25 DE DE602004004925T patent/DE602004004925T2/de not_active Expired - Fee Related
- 2004-10-25 DK DK04762951T patent/DK1682129T3/da active
-
2005
- 2005-12-20 US US11/312,661 patent/US20060154974A1/en not_active Abandoned
-
2006
- 2006-03-20 IS IS8364A patent/IS8364A/is unknown
- 2006-04-25 CO CO06039105A patent/CO5690582A2/es not_active Application Discontinuation
- 2006-04-25 IL IL175189A patent/IL175189A0/en unknown
- 2006-05-26 NO NO20062417A patent/NO20062417L/no not_active Application Discontinuation
-
2007
- 2007-04-19 CY CY20071100529T patent/CY1106526T1/el unknown
- 2007-05-07 HR HR20070194T patent/HRP20070194T3/xx unknown
-
2008
- 2008-12-19 US US12/339,438 patent/US20090247593A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2279414T3 (es) | 2007-08-16 |
| BRPI0415661A (pt) | 2006-12-19 |
| SI1682129T1 (sl) | 2007-06-30 |
| EP1682129B1 (en) | 2007-02-21 |
| PL1682129T3 (pl) | 2007-07-31 |
| KR20060093726A (ko) | 2006-08-25 |
| MEP6708A (xx) | 2010-02-10 |
| TW200524887A (en) | 2005-08-01 |
| EA200801734A1 (ru) | 2008-12-30 |
| US20090247593A1 (en) | 2009-10-01 |
| DK1682129T3 (da) | 2007-06-11 |
| WO2005039572A1 (en) | 2005-05-06 |
| ATE354365T1 (de) | 2007-03-15 |
| MXPA06004436A (es) | 2006-06-20 |
| IS8364A (is) | 2006-03-20 |
| AU2004283019A1 (en) | 2005-05-06 |
| DE602004004925T2 (de) | 2007-10-31 |
| IL175189A0 (en) | 2006-09-05 |
| RS20060289A (en) | 2008-06-05 |
| EP1803455A1 (en) | 2007-07-04 |
| US20060154974A1 (en) | 2006-07-13 |
| CA2542816A1 (en) | 2005-05-06 |
| SG147472A1 (en) | 2008-11-28 |
| EA010790B1 (ru) | 2008-10-30 |
| DE602004004925D1 (de) | 2007-04-05 |
| CY1106526T1 (el) | 2012-01-25 |
| HRP20070194T3 (en) | 2007-06-30 |
| EP1682129A1 (en) | 2006-07-26 |
| EA200600860A1 (ru) | 2006-08-25 |
| PT1682129E (pt) | 2007-04-30 |
| JP2007509083A (ja) | 2007-04-12 |
| CO5690582A2 (es) | 2006-10-31 |
| NO20062417L (no) | 2006-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047621A1 (es) | Derivados de n-tiazol-2- il-benzamida | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PE20080067A1 (es) | DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR) | |
| HRP20180331T1 (hr) | Spojevi n-pirolidinil, n'pirazolil- urea, tiourea, gvanidin i cijanogvanidin kao inhibitori trka kinaze | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| RU2015122757A (ru) | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR030696A1 (es) | Derivados de hidroxi-1-azobenceno, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, proceso para preparar dichas composiciones, proceso para preparar dichos compuestos, metodo in vitro o ex vivo para aumentar la estimulacion de la maduracion | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| ES2714100T3 (es) | Compuestos de quinolina fusionados como inhibidores de mTor, pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |